Unicycive Therapeutics, Inc. 8K

Unicycive Therapeutics reported Q2 2026 results, disclosed an FDA Complete Response Letter tied to third-party manufacturing issues for its OLC NDA alongside an upcoming FDA facility inspection, and noted $61.4 million in liquidity with cash runway into 2027 as it advances launch preparation efforts.

On August 12, 2026, Unicycive Therapeutics, Inc. reported its unaudited financial results for the second quarter ended June 30, 2026 and provided a business update, highlighting that the FDA has issued a Complete Response Letter in June 2026 for the resubmitted NDA for oxylanthanum carbonate (OLC) citing previously identified third-party manufacturing deficiencies, that the FDA has now assigned a facility inspection to the third-party manufacturing vendor with no new clinical efficacy or safety concerns raised, and that the company ended the quarter with $61.4 million in cash, cash equivalents, and marketable securities, expects cash runway into 2027, and is continuing commercial launch preparations and stakeholder engagement activities for OLC while recording a significantly reduced net loss driven primarily by changes in warrant liability fair value.

Filing Facts

CIK

1766140

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-088061

Alert Tier

7